EpCAM-targeted CAR-T cell therapy in patients with advanced colorectal and gastric cancers

被引：7
|
作者：
Fang, W. [1 ]
Luo, T. [2 ]
Lu, Z. [2 ]
Zhang, H. [1 ]
Tong, C. [1 ]
Wang, S. [3 ]
Tang, F. [3 ]
Ai, G. [3 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Med Oncol, Hangzhou, Peoples R China
[2] Naval Med Univ, Changhai Hosp Shanghai, Affiliated Hosp 1, Gastroenterol, Shanghai, Peoples R China
[3] Suzhou Immunofoco Biotechnol Co Ltd, Med, Suzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.863
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
737MO
引用
收藏
页码：S880 / S881
页数：2
相关论文
共 50 条
  • [21] FDA approves first BCMA-targeted CAR-T cell therapy
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (05) : 332 - 332
  • [22] FDA approves second BCMA-targeted CAR-T cell therapy
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (04) : 249 - 249
  • [23] IMPROVING CEA-TARGETED CAR-T CELL THERAPY FOR SOLID TUMOURS
    Zheng, W.
    Kueberuwa, G.
    Cheadle, E.
    Armstrong, A.
    HUMAN GENE THERAPY, 2019, 30 (12) : A8 - A8
  • [24] Total Car-T Cost of Care Beyond the Price of Car-T Cell Therapy in Patients with Multiple Myeloma
    Jagannath, Sundar
    Joseph, Nedra
    Crivera, Concetta
    Jackson, Carolyn C.
    Valluri, Satish
    Cost, Patricia
    Phelps, Hilary
    Slowik, Rafal
    Klein, Timothy
    Yu, Xueting
    Smolen, Lee
    Cohen, Adam D.
    BLOOD, 2021, 138
  • [25] FDA approves second BCMA-targeted CAR-T cell therapy
    Asher Mullard
    Nature Reviews Drug Discovery, 2022, 21 : 249 - 249
  • [26] Management of Patients Undergoing CAR-T Cell Therapy in Germany
    Penack, Olaf
    Dreger, Peter
    Ajib, Salem
    Ayuk, Francis
    Baermann, Ben-Niklas
    Bug, Gesine
    Kriege, Oliver
    Jentzsch, Madlen
    Kobbe, Guido
    Koenecke, Christian
    Lutz, Mathias
    Martin, Sonja
    Schlegel, Paul-Gerhard
    Schroers, Roland
    von Tresckow, Bastian
    Vucinic, Vladan
    Subklewe, Marion
    Bethge, Wolfgang
    Wolff, Daniel
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (03) : 65 - 75
  • [27] CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy
    Hill, Joshua A.
    Giralt, Sergio
    Torgerson, Troy R.
    Lazarus, Hillard M.
    BLOOD REVIEWS, 2019, 38
  • [28] Cardiotoxic profiles of CAR-T therapy and bispecific T-cell engagers in hematological cancers
    Karthikeyan, Badri
    Sunder, Sunitha Shyam
    Puzanov, Igor
    Olejniczak, Scott H.
    Pokharel, Saraswati
    Sharma, Umesh C.
    COMMUNICATIONS MEDICINE, 2024, 4 (01):
  • [29] Phase I study of GCC CAR-T therapy IM96 in patients with advanced colorectal cancer
    Qi, C.
    Chang, L.
    Li, J.
    Gong, J.
    Wang, X.
    Wang, Z.
    Lu, X.
    He, T.
    Ding, Y.
    Wu, F.
    Liu, D.
    Shen, L.
    ANNALS OF ONCOLOGY, 2023, 34 : S620 - S620
  • [30] A mathematical model for optimization of combination therapy involving targeted radionuclide and CAR-T cell therapy
    Adhikarla, Vikram
    Awuah, Dennis
    Brummer, Alexander B.
    Caserta, Enrico
    Krishnan, Amrita
    Pichiorri, Flavia
    Minnix, Megan M.
    Shively, John E.
    Wong, Jeffrey Y. C.
    Wang, Xiuli
    Rockne, Russell C.
    CANCER RESEARCH, 2022, 82 (12)
12345